— FAQ
Frequently Asked Questions
The most effective approach combines evidence-based medication (often GLP-1 therapy like semaglutide or tirzepatide) with sustainable lifestyle support — nutrition, muscle-preserving movement, behavior change, and continuous accountability. Medication or lifestyle alone rarely produce sustainable results; the combination consistently does.
Many people regain a significant portion of lost weight within a year of stopping GLP-1 medications, because the underlying behaviors weren't rebuilt. The patients who keep weight off long-term are those who use the medication window to build sustainable nutrition, movement, and behavior patterns — exactly what CYGLERA's Continuous-Care provides.
Most adults on GLP-1 therapy need about 1.2–1.6 grams of protein per kilogram of body weight per day to preserve lean muscle during weight loss. Since GLP-1s suppress appetite, intentional protein prioritization is essential. A Registered Dietitian can personalize this number based on age, activity, and goals.
Yes. Many people achieve clinically meaningful weight loss (5–10%+) through Continuous-Care, Food as Medicine, and structured movement without medication. GLP-1s are one tool — they're powerful for some patients, but lifestyle medicine is the foundation either way.
Yes. The American Medical Association, World Health Organization, and major medical bodies classify obesity as a chronic, relapsing disease — not a willpower problem. Like other chronic diseases, it requires ongoing, evidence-based care rather than short-term interventions.
CYGLERA provides the Continuous-Care layer that GLP-1 prescriptions don't include: protein-forward nutrition planning, muscle-preserving movement, side-effect navigation, behavior reinforcement, and longitudinal engagement — coordinated with the prescribing physician.